How Nanotechnology can Improve Drug Formulations

🔬 Overcoming hurdles in mRNA therapeutics, scientists have developed a second near-infrared (NIR-II) lipid nanoparticle (LNP) approach to enhance mRNA delivery efficiency using a stimulus-responsive photothermal-promoted endosomal escape delivery (SPEED) strategy. 🌡️ How does it work? In the acidic endosomal environment, a specially designed pH-activated NIR-II dye-conjugated lipid (Cy-lipid) within the LNPs is protonated, turning on NIR-II absorption for light-to-heat conversion under 1064 nm laser irradiation. This heat triggers a change in the LNPs' morphology, promoting their rapid escape from the endosome. 📈 The result? Around a 3-fold increase in the translation capacity of enhanced green fluorescent protein (eGFP) encoding mRNA compared to the group without NIR-II light. Moreover, the bioluminescence intensity in the mouse liver region, induced by delivered luciferase encoding mRNA, showed a positive correlation with increasing radiation dose, validating the SPEED strategy. 🚀 This innovative approach offers a promising formulation strategy for the efficient delivery of therapeutic mRNA drugs with enhanced translation capability and therapeutic efficacy https://lnkd.in/eTsYEGYh #mRNATherapeutics #NIRIILNPs #DrugDelivery #SPEEDStrategy #Innovation #nanomaterials #nanoscience #nanotechnology #lipidnanoparticles #LNPs #strategy #work #translation

Newly reported therapy for #rheumatoidarthritis using PLGA nanoparticles containing methotrexate and gold for theranostics application. Rheumatoid arthritis, an autoimmune disorder, exerts a considerable effect on quality of life. The inflammatory mechanism involved in rheumatoid arthritis is not clearly known, and therefore the need to develop effective medicines as well as new methods for early detection is a challenge. In this study, we developed PLGA nanoparticles containing gold and methotrexate in core and anti-CD64 antibody conjugated to nanoparticle surface via coupling process. The nanoparticles were examined for their surface morphology using SEM and TEM. The mean particle size, zeta potential, and PDI values of nanoparticles were 413.6 ± 2.89 nm, −10.12 ± 2.12 mV, and 0.23 ± 0.04, respectively, indicating good stability and particle homogeneity. In vitro drug release revealed a controlled release pattern with 93.44 ± 1.60% up to 72 h of release in the presence of pH 5.8, indicating the influence of pH and NIR on drug release. In vivo results on adjuvant-induced arthritis on Wistar rats indicated that animals receiving antibody-conjugated nanoparticles showed improvement in clinical indices and arthritic score as compared to non-conjugated nanoparticles and free drugs. Learn how this system maximized therapeutic effectiveness by limiting dosage-related side effects. @sahil gandhi Pravin Shende AAPS PharmSciTech American Association of Pharmaceutical Scientists (AAPS) | @aapscomms Daniel Davis, Ph.D., PharmD QI (Tony) ZHOU Claudio Salomon Michael Repka AAPS NIPER Student Chapter #drugdelivery #drugdevelopment #nanoparticles #nanotechnology #antibodies Link: https://rdcu.be/dywZv

🟥 Nanotechnology and Delivery Systems in Cancer Immunotherapy Nanotechnology has revolutionized cancer immunotherapy by improving the precision, efficacy, and bioavailability of therapeutic agents. In particular, engineered nanocarriers can improve drug delivery, enhance immune activation, and overcome tumor-related barriers, resulting in more effective cancer treatments with reduced systemic toxicity. Nanoparticles can serve as effective delivery vehicles for immune checkpoint inhibitors, cytokines, and cancer vaccines. Lipid-based nanoparticles, such as those used for mRNA vaccines, can encapsulate and protect immunomodulators, thereby improving their stability and targeted delivery. Polymeric nanoparticles and inorganic nanocarriers, such as gold and silica nanoparticles, can provide controlled release mechanisms to ensure sustained immune stimulation at the tumor site. Nanotechnology also plays a key role in enhancing adoptive cell therapy, including CAR-T cell therapy. Nanoparticles can be used to deliver CRISPR-Cas9 systems for precise genetic modification, thereby improving the persistence and functionality of CAR-T cells. In addition, nanoparticle-coated CAR-T cells exhibit better tumor infiltration and resistance to immunosuppressive signals in the tumor microenvironment. Another key application is tumor microenvironment modulation. Nanoparticles can carry immunostimulatory molecules such as IL-2 and GM-CSF to reprogram the immune landscape of tumors, making them more susceptible to T cell attack. In addition, nanocarriers can deliver small molecule inhibitors that block immunosuppressive pathways, such as TGF-β or IDO, thereby enhancing immune checkpoint blockade efficacy. Nanotechnology also plays a role in advancing personalized immunotherapy. Nanoparticles can be engineered to carry patient-specific tumor antigens, enabling highly personalized cancer vaccine development. These personalized approaches can both enhance immune responses while reducing off-target effects. In summary, with continued advances in biocompatibility, targeting efficiency, and controlled release mechanisms, nanotechnology-based delivery systems are transforming cancer immunotherapy, providing precise, safer, and more effective treatment options for solid and hematological malignancies. References [1] Forough Shams et al., Mol Biol Rep 2021 (doi: 10.1007/s11033-021-06876-y) [2] Lili Zhou et al., Front Oncol 2022 (doi: 10.3389/fonc.2022.864301) #Nanotechnology #Immunotherapy #CancerResearch #PrecisionMedicine #DrugDelivery #CAR_TCells #CheckpointInhibitors #TumorMicroenvironment #BiomedicalInnovation #OncologyBreakthroughs #LifeSciences